Who Paid My Doc
Ozgen Dogan
Cardiovascular Disease Brooklyn, NY Medical Doctor
NPI 1841392131 CMS profile 129393
50 Court St Fl 12, Brooklyn, NY 11201
General payments
$290,425
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$113,784
Through program year 2025, Ozgen Dogan of Brooklyn, NY is reported in the CMS Open Payments database as having received $290,425 across 306 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $113,784 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,875 | 18 | |
| 2024 | General | $24,850 | 17 | |
| 2023 | General | $29,772 | 33 | |
| 2022 | General | $54,132 | 61 | |
| 2021 | General | $52,514 | 61 | |
| 2020 | General | $56,887 | 62 | |
| 2019 | General | $50,395 | 54 |
Beside peers
- Ozgen Dogan
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Ozgen Dogan were reported at $21,875. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Ozgen Dogan | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $50,395 | $450 | $127–$1,392 | $163 |
| 2020 | $56,887 | $242 | $77–$751 | $114 |
| 2021 | $52,514 | $335 | $101–$1,037 | $132 |
| 2022 | $54,132 | $395 | $121–$1,211 | $149 |
| 2023 | $29,772 | $443 | $136–$1,283 | $160 |
| 2024 | $24,850 | $450 | $136–$1,323 | $164 |
| 2025 | $21,875 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
2,764
Drug cost
$306,938
Branded share of claims
26.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 169 | $202,932 | |
| Entresto Sacubitril/Valsartan | Brand | 36 | $46,559 | |
| Xarelto Rivaroxaban | Brand | 11 | $13,677 | |
| Januvia Sitagliptin Phosphate | Brand | 11 | $10,899 | |
| Metoprolol Succinate | Generic | 199 | $2,939 | |
| Atorvastatin Calcium | Generic | 258 | $2,910 | |
| Losartan Potassium | Generic | 242 | $2,894 | |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | Brand | 145 | $2,532 | |
| Amlodipine Besylate | Generic | 387 | $2,096 | |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | Brand | 117 | $1,726 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Billing to Medicare
Part B · data year 2024 · 50 billing codesPaid by Medicare
$312,367
Medicare patients
561
Services billed
3,872
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 55% | |
| Arthritis | 53% | |
| Ischemic heart disease | 41% | |
| Chronic kidney disease | 38% | |
| Heart failure | 32% | |
| Atrial fibrillation | 24% | |
| Osteoporosis | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90653 | Office | 12 | 12 | $982 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
306 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in New York
Roger Hajjar
Cardiovascular Disease · New York, NY
Szilard Voros
Cardiovascular Disease · Stony Brook, NY
Gregg Stone
Cardiovascular Disease · New York, NY
Augustin Delago
Cardiovascular Disease · Albany, NY
Philippe Genereux
Cardiovascular Disease · New York, NY
Adam Rosenbluth
Cardiovascular Disease · New York, NY
Related records
Cardiovascular Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.